[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$ucbjy Graphic](https://lunarcrush.com/gi/w:26/t:$ucbjy.png) $ucbjy

$UCBJY sees increased mentions and creator activity. Positive sentiment around clinical trial developments is driving engagement.

### About $ucbjy
A cryptocurrency or stock ticker symbol.  

### Insights [#](/topic/$ucbjy/insights)
- $ucbjy mentions is up XXXXX% from the previous X months.

### Engagements: X [#](/topic/$ucbjy/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$ucbjy/c:line/m:interactions.svg)  
[Engagements 24-Hour Chart Data](/topic/$ucbjy/time-series/interactions.tsv)  
**Current Value**: X  
**Daily Average**: XXX  
**1 Month**: XXXXX +24%  
**1-Year High**: XXXXX on 2025-04-29  
**1-Year Low**: X on 2025-05-10  

| Social Network | X |
| -------------- | - |
| Engagements    | X |
  

  
  
### Mentions: X [#](/topic/$ucbjy/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$ucbjy/c:line/m:posts_active.svg)  
[Mentions 24-Hour Chart Data](/topic/$ucbjy/time-series/posts_active.tsv)  
**Current Value**: X  
**Daily Average**: X  
**1 Week**: X +100%  
**1 Month**: XX +38%  
**1-Year High**: X on 2025-04-29  
**1-Year Low**: X on 2025-04-27  

| Social Network | X |
| -------------- | - |
| Mentions       | X |
  

  
  
### Creators: X [#](/topic/$ucbjy/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$ucbjy/c:line/m:contributors_active.svg)  
[Creators 24-Hour Chart Data](/topic/$ucbjy/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $ucbjy in the last XX hours which is down XX% from X in the previous XX hours
**Daily Average**: X  
**1 Week**: X no change  
**1 Month**: X +50%  
**1-Year High**: X on 2025-04-29  
**1-Year Low**: X on 2025-04-27  

The most influential creators that mention $ucbjy in the last XX hours

| Creator                                    | Rank | Followers | Posts | Engagements |
| -------                                    | ---- | --------- | ----- | ----------- |
| [@Quantumup1](/creator/twitter/Quantumup1) | X    | XXXXX     | X     | XXX         |

[View More](/list/creators/$ucbjy/100)

**Top assets mentioned**
In the posts about $ucbjy in the last XX hours

[Johnson & Johnson (JNJ)](/topic/$jnj)
[Oruka Therapeutics, Inc. Common Stock (ORKA)](/topic/$orka)
[AbbVie Inc (ABBV)](/topic/$abbv)

**Top topics mentioned**
In the posts about $ucbjy in the last XX hours

[$jnj](/topic/$jnj), [$orkas](/topic/$orkas), [$orka](/topic/$orka), [spe](/topic/spe), [$wcrs](/topic/$wcrs), [$tyhoy](/topic/$tyhoy), [$trrvf](/topic/$trrvf), [$abbv](/topic/$abbv), [hc](/topic/hc)

### Top Social Posts [#](/topic/$ucbjy/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"H.C. Wainwright reit'd $ORKA Buy/$45 after Oruka📰that the FDA had cleared its IND application for its Phase 2a trial of ORKA-001 (the company's long-acting anti-IL-23p19 antibody) in moderate-to-severe PsO called EVERLAST-A. $ABBV $PTGX - $JNJ #EDAV25 H.C. Wainwright said in its note: "This program is a randomized double-blind placebo-controlled Phase 2a trial designed to evaluate the safety and efficacy of a single dose level of ORKA-001 in moderate-to-severe psoriasis patients. EVERLAST-A will enroll approximately XX patients randomized 3:1 to receive ORKA-001 or matching placebo. The"  
[@Quantumup1](/creator/x/Quantumup1) on [X](/post/tweet/1948085842020590074) 2025-07-23 18:20:33 UTC 3529 followers, 1203 engagements


"💰 $AACAY $AMIGY $BCKIY $BIRDF $CAIXY $CLST $COST $CPHRF $CQP $DELKY $DLMAF $EFSG $ESYJY $FMS $GATX $GBOOY $GVDNY $JBTC $JINFF $MCCRF $MITFY $MLLGF $MQBKY $MTYFF $PRMRF $PSYTF $PUGBY $RDWR $RECT $RLGT $SEKEY $SPE $TCYSF $TMXXF $TRRVF $TYHOY $UCBJY $WCRS Like 😎 🙏 #Unus"  
[@JimyTuits](/creator/x/JimyTuits) on [X](/post/tweet/1948021533273932028) 2025-07-23 14:05:00 UTC XXX followers, XX engagements


"Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt. $ABBV $PTGX $JNJ #EADV25 $UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating"  
[@Quantumup1](/creator/x/Quantumup1) on [X](/post/tweet/1947283589118198123) 2025-07-21 13:12:41 UTC 3530 followers, 4206 engagements